A breakthrough oral formulation of glucagon-like peptide-1 (GLP-1) receptor agonist has demonstrated efficacy comparable to established injectable therapies in managing type 2 diabetes, according to phase 3 trial results presented at a major diabetes research conference. The medication achieved significant improvements in both glycaemic control and weight reduction, with over 70% of participants experiencing clinically meaningful outcomes across both endpoints simultaneously.
This advancement addresses a critical clinical challenge: medication adherence. While injectable GLP-1 agents have revolutionized diabetes management, patient preference for oral medications remains a substantial barrier to treatment initiation and continuation. The new oral formulation maintains therapeutic efficacy while offering the convenience of pill-based dosing.
Regulatory pathways have been activated, with market availability anticipated within 18-24 months. These findings are expected to inform updated treatment guidelines and significantly expand access to GLP-1 therapy among the broader type 2 diabetes population.
Read the full article on GMJ Newsroom.
Was this article helpful?
